Corcept Therapeutics Management
Management criteria checks 2/4
Corcept Therapeutics' CEO is Joseph Belanoff, appointed in Jan 1999, has a tenure of 25.42 years. total yearly compensation is $9.34M, comprised of 11.6% salary and 88.4% bonuses, including company stock and options. directly owns 2.72% of the company’s shares, worth $85.33M. The average tenure of the management team and the board of directors is 3.6 years and 22.7 years respectively.
Key information
Joseph Belanoff
Chief executive officer
US$9.3m
Total compensation
| CEO salary percentage | 11.6% |
| CEO tenure | 25.4yrs |
| CEO ownership | 2.7% |
| Management average tenure | 3.6yrs |
| Board average tenure | 22.7yrs |
Recent management updates
Recent updates
With Corcept Therapeutics Incorporated (NASDAQ:CORT) It Looks Like You'll Get What You Pay For
Apr 15
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit
Feb 22Corcept Therapeutics: Key Catalysts Ahead
Feb 19After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar
Dec 23Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price
Nov 07Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?
Jun 23Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)
Feb 16Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today
Jan 11Corcept Therapeutics starts phase 2 trial of its ALS treatment
Oct 11Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?
Sep 27Corcept extends distribution agreement for Cushing’s syndrome drug
Sep 23Corcept Therapeutics: A Status Check
Sep 06Corcept cut to Hold at Truist on balanced risk-reward setup
Aug 01Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer
Jun 29I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease
Jun 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$117m |
| Dec 31 2023 | US$9m | US$1m | US$105m |
| Sep 30 2023 | n/a | n/a | US$91m |
| Jun 30 2023 | n/a | n/a | US$94m |
| Mar 31 2023 | n/a | n/a | US$94m |
| Dec 31 2022 | US$7m | US$896k | US$101m |
| Sep 30 2022 | n/a | n/a | US$117m |
| Jun 30 2022 | n/a | n/a | US$113m |
| Mar 31 2022 | n/a | n/a | US$112m |
| Dec 31 2021 | US$11m | US$844k | US$113m |
| Sep 30 2021 | n/a | n/a | US$106m |
| Jun 30 2021 | n/a | n/a | US$98m |
| Mar 31 2021 | n/a | n/a | US$99m |
| Dec 31 2020 | US$6m | US$770k | US$106m |
| Sep 30 2020 | n/a | n/a | US$109m |
| Jun 30 2020 | n/a | n/a | US$114m |
| Mar 31 2020 | n/a | n/a | US$106m |
| Dec 31 2019 | US$5m | US$708k | US$94m |
| Sep 30 2019 | n/a | n/a | US$87m |
| Jun 30 2019 | n/a | n/a | US$78m |
| Mar 31 2019 | n/a | n/a | US$76m |
| Dec 31 2018 | US$6m | US$680k | US$75m |
| Sep 30 2018 | n/a | n/a | US$152m |
| Jun 30 2018 | n/a | n/a | US$148m |
| Mar 31 2018 | n/a | n/a | US$142m |
| Dec 31 2017 | US$4m | US$647k | US$129m |
Compensation vs Market: Joseph's total compensation ($USD9.34M) is above average for companies of similar size in the US market ($USD6.71M).
Compensation vs Earnings: Joseph's compensation has increased by more than 20% in the past year.
CEO
Joseph Belanoff (67 yo)
25.4yrs
Tenure
US$9,337,734
Compensation
Dr. Joseph K. Belanoff, M.D., is a Co-Founder of Corcept Therapeutics Incorporated and has been its Chief Executive Officer since 1999 and President since 2014. Dr. Belanoff has been a Faculty Member and h...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 25.4yrs | US$9.34m | 2.72% $ 85.3m | |
| CFO & Treasurer | 3.3yrs | US$3.72m | 0.0092% $ 287.3k | |
| President of Endocrinology | 8.2yrs | US$3.91m | 0.10% $ 3.2m | |
| Chief Development Officer | 2.8yrs | US$3.86m | 0.0058% $ 181.9k | |
| Chief Business Officer & Secretary | 10.4yrs | US$3.96m | 0.044% $ 1.4m | |
| Chief Accounting & Technology Officer | 3.9yrs | no data | 0.0070% $ 220.5k | |
| Chief Scientific Officer | 3.9yrs | US$3.11m | 0.090% $ 2.8m | |
| Chief Human Resources & Communications Officer | 2.9yrs | no data | no data | |
| President of Emerging Markets | less than a year | no data | no data | |
| President of Oncology | less than a year | no data | no data |
3.6yrs
Average Tenure
53.5yo
Average Age
Experienced Management: CORT's management team is considered experienced (3.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 25.4yrs | US$9.34m | 2.72% $ 85.3m | |
| Independent Director | 25.4yrs | US$492.53k | 5.1% $ 160.0m | |
| Independent Director | 19.9yrs | US$509.03k | 1.26% $ 39.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Chairman | 25.4yrs | US$1.26m | 2.13% $ 66.7m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.3yrs | US$511.53k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 4.8yrs | US$488.53k | 0% $ 0 |
22.7yrs
Average Tenure
68.5yo
Average Age
Experienced Board: CORT's board of directors are seasoned and experienced ( 22.7 years average tenure).